Program
Simvastatin
Also written as “simvastatin”, “ezetimibe (+) simvastatin” and “Fenofibrate/Simvastatin”.
Its studies are mostly in Hypercholesterolemia · Diabetes Mellitus, Type 2 · Hyperlipidemias · Cardiovascular Diseases · Hypertension, led by 11 companies.
Drug pageSimvastatin: every studyMany companies study it; this page follows only the 65 they lead. All 370 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 290 open or running | phase 4since Sep 7, 2005 | Sep 21, 2004 | none ahead |
| Abbottits history only | 80 open or running | phase 3since Mar 25, 2004 | Mar 25, 2004 | none ahead |
| Eli Lillyits history only | 60 open or running | phase 2since Apr 15, 2010 | Apr 15, 2010 | none ahead |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Oct 28, 2005 | Oct 28, 2005 | none ahead |
| Merckits history only | 60 open or running | phase 3since May 24, 2007 | May 24, 2007 | none ahead |
| Pfizerits history only | 40 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jul 21, 2010 | Jul 21, 2010 | none ahead |
| Biogenits history only | 10 open or running | phase 4since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| Entero Therapeuticsits history only | 10 open or running | early phase 1since Oct 3, 2016 | Oct 3, 2016 | none ahead |
| Medtronicits history only | 10 open or running | early phase 1since Jul 21, 2008 | Jul 21, 2008 | none ahead |
| Viatrisits history only | 10 open or running | phase 4since Aug 30, 2005 | Aug 30, 2005 | none ahead |
Also a collaborator on its studies: Immunogenics, Regeneron Pharmaceuticals, Celerion and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Aug 2, 2005.
- Jul 1, 2010Phase 1 study in Sleep Wake DisordersGlaxoSmithKline · NCT01299597 · 30 enrolled · Germany
- Jul 21, 2010Dr. Reddy's Laboratories’ first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01167933, NCT01167894
- Apr 13, 2011Phase 3 study in HypercholesterolemiaMerck · NCT01335997 · 1,139 enrolled
- Oct 29, 2011Phase 1 study in Diabetes Mellitus, Type 2Pfizer · NCT01469468 · 14 enrolled · United States
- Jun 26, 2012Phase 3 study in DyslipidemiasAbbott · NCT01674712 · 575 enrolled · Argentina, Czech Republic, Germany and more
- Aug 31, 2012Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT01678820 · 299 enrolled
- Sep 26, 2013Phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT01953835 · 37 enrolled · United States
- Oct 8, 2013Phase 1 study in Healthy VolunteersEli Lilly · NCT01960140 · 40 enrolled · United Kingdom
- May 28, 2014Phase 1 study in Healthy VolunteersEli Lilly · NCT02156492 · 62 enrolled · China
- Nov 20, 2014Phase 1 study in Healthy VolunteersEli Lilly · NCT02300259 · 48 enrolled · United States
- Mar 16, 2016Phase 1 study in DyslipidemiasEli Lilly · NCT02714569 · 60 enrolled · United States
- Oct 3, 2016Entero Therapeutics’ first study: early phase 1 study in Celiac DiseaseNew to Entero TherapeuticsEntero Therapeutics · NCT03011931 · 40 enrolled · United States
- Mar 6, 2019Phase 3 study in Hyperlipoproteinemia Type IIOrganon · NCT03884452 · 50 enrolled
- Dec 16, 2023Phase 1 study in ObesityEli Lilly · NCT06186622 · 50 enrolled · United States
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
The newest 60 of 65 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06186622Obesity · United States | 1 | Completed | Eli Lilly | Jul 10, 2024 | 50 |
| NCT03884452Hyperlipoproteinemia Type II | 3 | Completed | Organon | May 24, 2001 | 50 |
| NCT03011931Celiac Disease · United States | Early 1 | Completed | Entero Therapeutics | Jan 2019 | 40 |
| NCT02714569Dyslipidemias · United States | 1 | Completed | Eli Lilly | Feb 15, 2017 | 60 |
| NCT02300259Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Apr 2015 | 48 |
| NCT02156492Healthy Volunteers · China | 1 | Completed | Eli Lilly | Dec 2014 | 62 |
| NCT01960140Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Dec 2013 | 40 |
| NCT01953835Lupus Erythematosus, Systemic · United States | 1 | Completed | GlaxoSmithKline | Mar 10, 2014 | 37 |
| NCT01678820Diabetes Mellitus, Type 2 | 3 | Terminated | Merck | Nov 1, 2013 | 299 |
| NCT01674712Dyslipidemias · Argentina, Czech Republic, Germany and more | 3 | Completed | Abbott | Oct 2013 | 575 |
| NCT01469468Diabetes Mellitus, Type 2 · United States | 1 | Completed | Pfizer | Dec 2011 | 14 |
| NCT01335997Hypercholesterolemia | 3 | Terminated | Merck | Jan 1, 2012 | 1,139 |
| NCT01167933Healthy | 1 | Completed | Dr. Reddy's Laboratories | Apr 2005 | 44 |
| NCT01167894Healthy | 1 | Completed | Dr. Reddy's Laboratories | Apr 2005 | 72 |
| NCT01299597Sleep Wake Disorders · Germany | 1 | Completed | GlaxoSmithKline | Feb 26, 2010 | 30 |
| NCT01138072Infections · United States | 1 | Completed | GlaxoSmithKline | Aug 2010 | 14 |
| NCT01105975Dyslipidemias · United States, Denmark, Germany and more | 2 | Completed | Eli Lilly | Jun 2011 | 398 |
| NCT01101568Diabetes Mellitus, Type 2 · United States | 1 | Completed | GlaxoSmithKline | Jun 24, 2010 | 28 |
| NCT00943124Dyslipidemias | 1 | Completed | Merck | Aug 2007 | 220 |
| NCT00935259Hypercholesterolemia | 1 | Completed | Merck | Oct 2009 | 31 |
| NCT00862251Cardiovascular Diseases | 3 | Completed | Organon | Mar 2011 | 808 |
| NCT00739050Lupus Erythematosus, Systemic | 4 | Terminated | Organon | Feb 1, 2008 | 4 |
| NCT00720577Peripheral Arterial Disease | Early 1 | Completed | Medtronic | Jul 2007 | 164 |
| NCT00654628Hypercholesterolemia | 4 | Completed | Organon | Jul 1, 2009 | 173 |
| NCT00653835Hypercholesterolemia | 4 | Completed | Organon | Aug 1, 2004 | 153 |
| NCT00653523Hypercholesterolemia | 3 | Completed | Organon | Jun 1, 2009 | 151 |
| NCT00652301Cholesterol | 3 | Completed | Organon | Apr 2004 | 40 |
| NCT00651560Hyperlipidemias | 3 | Completed | Organon | Dec 23, 2005 | 167 |
| NCT00651391Hypercholesterolemia | 3 | Terminated | Organon | Sep 1, 2004 | 28 |
| NCT00650819Hypercholesterolemia | 3 | Completed | Organon | Feb 1, 2005 | 240 |
| NCT00650663Hypercholesterolemia | 4 | Completed | Organon | Sep 1, 2004 | 247 |
| NCT00566267Hyperlipidemias | 3 | Completed | Merck | 58 | |
| NCT00551447Coronary Disease | 3 | Completed | Organon | Mar 2003 | 616 |
| NCT00504439Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | GlaxoSmithKline | Sep 6, 2007 | 36 |
| NCT00496730Hypercholesterolemia | 3 | Completed | Organon | Aug 2008 | 256 |
| NCT00492765Multiple Sclerosis · Denmark | 4 | Completed | Biogen | Apr 2010 | 380 |
| NCT00479713Hypercholesterolemia | 3 | Completed | Organon | Mar 1, 2008 | 618 |
| NCT00479388Primary Hypercholesterolemia | 3 | Completed | Merck | Jul 2008 | 1,216 |
| NCT00465088Hyperlipidemias · United States | 3 | Completed | Abbott | Feb 2008 | 199 |
| NCT00462748Hypercholesterolemia | 3 | Completed | Organon | Jun 2008 | 786 |
| NCT00442897Hypercholesterolemia | 4 | Completed | Organon | Oct 2008 | 229 |
| NCT00423579Hypercholesterolemia | 4 | Completed | Organon | Mar 1, 2008 | 120 |
| NCT00413972Hypercholesterolemia | 3 | Completed | Organon | Nov 2006 | 392 |
| NCT00409773Hypercholesterolemia | 3 | Completed | Organon | Jul 2008 | 1,143 |
| NCT00398294Hypercholesterolemia · Taiwan | 4 | Completed | Organon | Apr 4, 2006 | 30 |
| NCT00389896HDL Cholesterol | 3 | Completed | Organon | Oct 4, 2002 | 150 |
| NCT00362934Hyperlipidemias · Bulgaria, Czech Republic, Germany and more | 3 | Completed | Abbott | Aug 2008 | 516 |
| NCT00362206Hyperlipidemias · Greece, Israel, Romania and more | 3 | Completed | Abbott | Sep 2008 | 423 |
| NCT00352183Cardiovascular Diseases · Australia, Estonia, Hungary and more | 3 | Completed | Abbott | Aug 2008 | 450 |
| NCT00349375Hyperlipidemias · Czech Republic, Denmark, France and more | 3 | Completed | Abbott | Sep 2008 | 1,040 |
| NCT00271817Hypercholesterolemia | 3 | Completed | Organon | Feb 2008 | 1,220 |
| NCT00267280Hyperlipidemias · United States | 3 | Terminated | Pfizer | Dec 2006 | 640 |
| NCT00267254Hyperlipidemias · United States | 3 | Completed | Pfizer | 640 | |
| NCT00246701Hypertriglyceridemia | 3 | Completed | GlaxoSmithKline | Jun 1, 2006 | 256 |
| NCT00166530Atherosclerosis | 4 | Completed | Organon | Feb 2007 | 367 |
| NCT00166504Hypercholesterolemia | 4 | Completed | Organon | Oct 2007 | 203 |
| NCT00159835Cardiovascular Diseases · Denmark, Finland, Iceland and more | 4 | Completed | Pfizer | 8,600 | |
| NCT00157924Hypercholesterolemia | 4 | Completed | Organon | Sep 2007 | 190 |
| NCT00141141Hypercholesterolemia · Italy | 4 | Completed | Viatris | 383 | |
| NCT00132717Hypercholesterolemia | 3 | Completed | Organon | Jun 1, 2007 | 450 |
How it is read
Names in the registry
- “Simvastatin”, 44 entries
- “simvastatin”, 14 entries
- “ezetimibe (+) simvastatin”, 9 entries
- “Fenofibrate/Simvastatin”, 5 entries
- “Ezetimibe + Simvastatin”, 4 entries
Codes read as this program: MK0733.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 35 studies
- Diabetes Mellitus, Type 2, 9 studies
- Hyperlipidemias, 7 studies
- Cardiovascular Diseases, 3 studies
- Hypertension, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.